Abstract:The aggregation of amyloid-beta protein (A beta) into fibrillary deposits is implicated in Alzheimer's disease (AD), and inhibiting A beta aggregation and clearing A beta fibrils are considered as promising strategies to treat AD. It has been reported that resveratrol (RSV) and epigallocatechin-3-gallate (EGCG), two of the most extensively studied natural polyphenols, are able to inhibit A beta fibrillization and remodel the preformed fibrillary aggregates into amorphous, non-toxic species. However, the mechanisms by which RSV inhibits A beta(42) aggregation and disrupts A beta(42) protofibril, as well as the inhibitory/disruptive mechanistic similarities and differences between RSV and EGCG, remain mostly elusive. Herein, we performed extensive all-atom molecular dynamics (MD) simulations on A beta(42) dimers (the early aggregation state of A beta(42)) and protofibrils (the intermediate of A beta(42) fibril formation and elongation) in the absence/presence of RSV or EGCG molecules. Our simulations show that both RSV and EGCG can bind with A beta(42) monomers and inhibit the dimerization of A beta(42). The binding of RSV with A beta(42) peptide is mostly via pi-pi stacking interactions, while the binding of EGCG with A beta(42) is mainly through hydrophobic, pi-pi stacking, and hydrogen-bonding interactions. Moreover, both RSV and EGCG disrupt the beta-sheet structure and K28-A42 salt bridges, leading to a disruption of A beta(42) protofibril structure. RSV mainly binds with residues whose side-chains point inwards from the surface of the protofibril, while EGCG mostly binds with residues whose side-chains point outwards from the surface of the protofibril. Furthermore, RSV interacts with A beta(42) protofibrils mostly via pi-pi stacking interactions, while EGCG interacts with A beta(42) protofibrils mainly via hydrogen-bonding and hydrophobic interactions. For comparison, we also explore the effects of RSV/EGCG molecules on the aggregation inhibition and protofibril disruption of the Iowa mutant (D23N) A beta. Our findings may pave the way for the design of more effective drug candidates as well as the utilization of cocktail therapy using RSV and EGCG for the treatment of AD.

The mechanisms of flavonoids inhibiting conformational transition of amyloid-β42 monomer: a comparative molecular dynamics simulation study

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Molecular Simulations of Amyloid Structures, Toxicity, and Inhibition

Synthesis and Biological Evaluation of Deferiprone-Resveratrol Hybrids As Antioxidants, Aβ1–42 Aggregation Inhibitors and Metal-Chelating Agents for Alzheimer's Disease

Exploring the Molecular Structural Requirements of Flavonoids as Beta- Secretase-1 Inhibitors Using Molecular Modeling Studies

Dissecting the Inhibitory Mechanism of the Αb-Crystallin Domain Against Aβ42 Aggregation and Its Effect on Aβ42 Protofibrils: A Molecular Dynamics Simulation Study

Molecular mechanisms of resveratrol and EGCG in the inhibition of A<sub>42</sub> aggregation and disruption of A<sub>42</sub> protofibril: similarities and differences

Five Similar Anthocyanidin Molecules Display Distinct Disruptive Effects and Mechanisms of Action on Aβ1–42 Protofibril: A Molecular Dynamic Simulation Study

Five similar anthocyanidin molecules display distinct disruptive effects and mechanisms of action on Aβ 1–42 protofibril: A molecular dynamic simulation study

Understanding the Molecular Mechanisms of Polyphenol Inhibition of Amyloid β Aggregation

Flavanone glycosides inhibit β-site amyloid precursor protein cleaving enzyme 1 and cholinesterase and reduce Aβ aggregation in the amyloidogenic pathway

Recent Studies On Mechanisms Of New Drug Candidates For Alzheimer'S Disease Interacting With Amyloid-Beta Protofibrils Using Molecular Dynamics Simulations

Structural Optimization and Biological Evaluation of Substituted Bisphenol A Derivatives As Beta-Amyloid Peptide Aggregation Inhibitors.

Binding Research on Flavone Derivatives As Probes for Beta-Amyloid Plaques

Evaluation of Natural Flavonoid Compounds in Amyloid-β (Aβ) Inhibition for Alzheimer’s Disease Treatment

In Silico Study of Recognition Between Aβ40 and Aβ40 Fibril Surfaces: an N-Terminal Helical Recognition Motif and Its Implications for Inhibitor Design

Molecular Insights into the Inhibition and Disaggregation Effects of EGCG on Aβ40 and Aβ42 Cofibrillation

Molecular Dynamics Simulation Study on Conformational Behavior of Aβ(1–40) and Aβ(1–42) in Water and Methanol

Conformational Transition Of Amyloid Beta-Peptide

Natural Stereoisomeric Flavonoids Exhibit Different Disruptive Effects and the Mechanism of Action on Aβ42 Protofibril